| Bioactivity | Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide[1][2][3]. |
| Name | Bufrolin |
| CAS | 54867-56-0 |
| Formula | C18H16N2O6 |
| Molar Mass | 356.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. MacKenzie AE, et al. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol. 2014 Jan;85(1):91-104. [2]. Church M K, et al. Comparison of sodium cromoglycate derivatives, anti-histamines and β-stimulants on histamine release from human lung in vitro[J]. International Archives of Allergy and Immunology, 1981, 66(Suppl. 1): 281-282. [3]. Tymianski M, et al. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory: United States, US8933013 B2. 2015-01-13. |